Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).

ABSTRACT:

SUBMITTER: Metro G 

PROVIDER: S-EPMC9096286 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature